This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D66 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Hemophilia NOS (hemophilia, unspecified), Hemophilia NOS, Hemophilia unspecified, unclassified hemophilia, hemophilia of unidentified type |
| C. Adult onset | Possibility of first onset in adulthood is not low — NOS (unspecified) hemophilia is diagnosed when the type has not been identified, and includes cases in which mild hemophilia A or B is first identified in adulthood in connection with surgery or trauma; it is also sometimes used as a temporary diagnosis code before type-confirmation testing is performed. |
| 1. History | From the era of hemophilia as a single concept (before 1952) to the temporary role of the NOS code after type classification |
| 2. Causes | X-linked recessive inheritance, variants in the FVIII or FIX gene (type not yet confirmed) |
| 3. Genetics | Variants in the F8 (Xq28) or F9 (Xq27.1) gene; when the type is unconfirmed, isolated APTT prolongation is the common finding |
| 4. General epidemiology | 1 in 5,000–15,000 males; no separate epidemiological statistics exist for the NOS classification itself |
| 5. Pathophysiology | Defect in the intrinsic coagulation pathway → reduced tenase complex function → insufficient FX activation → reduced thrombin generation → bleeding |
| 6. Symptoms | Severe: spontaneous hemarthrosis and muscle hematomas; moderate: excessive bleeding after trauma; mild: delayed hemostasis after surgery or tooth extraction |
| 7. Signs | Isolated APTT prolongation, normal PT and platelets; reduction of either FVIII:C or FIX:C |
| 8. Screening | After APTT prolongation is found, simultaneous measurement of FVIII:C + FIX:C is mandatory to confirm the type |
| 9. Diagnosis | APTT → mixing study → measurement of FVIII:C + FIX:C → genetic testing; NOS is a temporary code before the type is confirmed |
| 10. Treatment | Temporary management with FFP before the type is confirmed; after confirmation, FVIII products/emicizumab for type A and FIX products/fitusiran for type B |
| 11. Prognosis | Normal life expectancy with type confirmation and appropriate treatment; risk of bleeding complications if treatment is delayed while the type remains unconfirmed |
| 12. Prevention | With a family history, confirm the type by genetic testing; classify by factor assays as soon as APTT prolongation is found |
| 13. References | WFH Guidelines for the Management of Haemophilia, 3rd ed. … and 9 other papers |
The history of hemophilia goes back to the dawn of human civilization. The ancient Talmud (2nd–5th century AD) contains a record exempting from circumcision a boy whose brothers had died of bleeding after circumcision, which is regarded as the first documented recognition that a bleeding tendency is inherited within families. In the 10th century, the Arab physician Al-Zahrawi (Albucasis) described a family of men who died of excessive bleeding after wounds, giving the first medical account of the concept of an inherited bleeding disorder.
The modern description was made in 1803 by the American physician John Conrad Otto. In his paper "An account of an hemorrhagic disposition existing in certain families," Otto clearly described that the disease is transmitted through mothers but manifests only in males. Later, in 1820, Nasse systematized this rule, establishing what became known as 'Nasse's law.' Up to this period, all males with an inherited bleeding tendency were in effect classified as having one and the same single disease — that is, from today's perspective, 'NOS (unspecified)' hemophilia.
The decisive turning point came in 1952. In first describing Christmas disease, the research team of Rosemary Biggs in the United Kingdom found that some hemophilia patients had a coagulation abnormality even though the then-known hemophilia factor (today's FVIII) was normal. They named this new factor Christmas factor, that is, coagulation factor IX (FIX). With this, 'hemophilia' was divided for the first time into type A (FVIII deficiency) and type B (FIX deficiency), and the concept of hemophilia before this distinction effectively corresponds to today's NOS concept.
In the ICD (International Classification of Diseases) system, the code D66 is originally assigned to hemophilia A (hereditary factor VIII deficiency), but in actual clinical practice NOS hemophilia refers to a temporary classification state before the type is confirmed, that is, before the results of FVIII:C and FIX:C measurements are available. This code is often assigned temporarily to patients in whom only APTT prolongation has been confirmed, in emergencies or while awaiting test results. In addition, some patients with mild hemophilia live for decades without a diagnosis and enter the diagnostic process when abnormal bleeding is first recognized in connection with surgery, trauma or tooth extraction in adulthood, and the NOS code is used at this initial stage. The trajectory of the history of hemophilia, from a single concept to type classification, well explains the historical context of the NOS classification itself.
Hemophilia NOS is an X-linked recessive inherited disorder caused by deficiency or dysfunction of coagulation factor VIII (FVIII) or coagulation factor IX (FIX), which play a key role in the blood coagulation process. The name NOS (Not Otherwise Specified) reflects a state in which the causative factor has not yet been confirmed.
X-linked recessive inheritance refers to a mode of inheritance in which, because the causative gene is located on the X chromosome, males (XY), who have only one X chromosome, develop the disease as soon as they carry the variant gene, whereas females (XX), who have two X chromosomes, remain carriers and mostly do not develop the disease if only one X chromosome carries the variant. However, carrier females may also have considerably reduced FVIII or FIX activity due to lyonization (random X-chromosome inactivation), and in such cases may experience mild bleeding symptoms.
FVIII deficiency (hemophilia A) accounts for about 80% of all hemophilia, and FIX deficiency (hemophilia B) for about 20%. In the NOS state, which of these two possibilities applies has not yet been confirmed. Rarely, a case may also be temporarily classified as NOS when both factors are at borderline levels or there is uncertainty in interpreting the test results.
Spontaneous mutations (de novo mutation) also account for some of the causes. About 30% of patients with hemophilia A and about 20% of patients with hemophilia B arise from new mutations without a clear family history. In such cases the diagnosis cannot be predicted from family history alone, and incidental findings on APTT testing or preoperative testing are often what lead to diagnosis. Acquired hemophilia is caused by autoantibodies against coagulation factors, but this is a separate category and is not classified under the NOS code.
The genetic background of hemophilia NOS lies in pathogenic variants of the F8 or F9 gene, and while the type is unconfirmed, both genes are considered candidates. The F8 gene is located at the distal end of the long arm of the X chromosome (Xq28) and is one of the largest genes in the human genome, spanning about 186 kb and consisting of 26 exons. The F9 gene is also located on the X chromosome (Xq27.1) and is a relatively small gene of about 34 kb with 8 exons.
The variant spectrum of the F8 gene is very broad. The most common variant causing severe hemophilia A (FVIII activity below 1%) is the intron 22 inversion, found in about 45–50% of severe patients. The intron 1 inversion accounts for about 5% of severe cases. Various types — point mutations (missense, nonsense), deletions, insertions, splicing variants — make up the rest, and more than 2,000 pathogenic variants have been reported to date. In the F9 gene, point mutations are also the most common, and there are variant types, such as hemophilia B Leyden, with a distinctive clinical course in which FIX levels rise spontaneously after puberty.
The genetic feature commonly identified in the NOS state, when the type is unconfirmed, is isolated prolongation of the APTT (activated partial thromboplastin time). When only the APTT is prolonged while the PT (prothrombin time) and platelet count are normal, deficiency or dysfunction of factors involved in the intrinsic coagulation pathway (FVIII, FIX, FXI, FXII, etc.) is suspected first. FVIII:C and FIX:C measurements confirm the type in most cases, but occasionally, when both tests are within the normal range and the APTT is prolonged, other causes such as FXI deficiency, FXII deficiency or lupus anticoagulant must be excluded.
Genetic testing is used after type confirmation to identify the exact kind of variant and is important for carrier identification within the family, prenatal diagnosis, and prediction of the risk of inhibitor development. MLPA (multiplex ligation-dependent probe amplification), inversion testing, direct sequencing (Sanger sequencing) and next-generation sequencing (NGS) are used.
Hemophilia occurs worldwide at a frequency of about 1 in 5,000–10,000 males (hemophilia A) or about 1 in 25,000–30,000 males (hemophilia B). According to the 2023 report of the World Federation of Hemophilia (WFH), about 320,000 hemophilia patients are registered worldwide, and it is estimated that in reality far more patients remain undiagnosed.
No independent epidemiological statistics are compiled separately for NOS (unspecified) hemophilia itself. Because the NOS classification generally reflects a temporary stage in the diagnostic process, it is absorbed in final counts into the numbers confirmed as type A or type B. However, in regions with limited medical resources, cases have been reported in which the NOS state persists for a long time because the infrastructure to measure FVIII:C and FIX:C separately is lacking.
In Korea, according to statistics from the Health Insurance Review & Assessment Service (HIRA) and the Korea Hemophilia Foundation, there are about 2,700–3,000 registered hemophilia patients in the country, of whom hemophilia A accounts for about 80% and hemophilia B for about 20%. It is designated for Special Copayment Reduction registration (V009) in Korea, so after rare disease registration the copayment rate for related medical expenses is reduced to 10% for 5 years. Some mild patients are diagnosed for the first time only in adulthood, and the NOS code is used at this initial point.
Reflecting X-linked inheritance, the sex distribution is overwhelmingly male, but carrier females may also show bleeding symptoms due to reduced activity, in which case they are managed as symptomatic carriers. It occurs at similar frequencies in all races and ethnic groups, with some regional differences in the gene variant spectrum.
The pathophysiology of hemophilia NOS is based on a defect in the intrinsic pathway of the coagulation cascade. In normal coagulation, when vascular injury occurs, the extrinsic pathway (tissue factor + FVII) and the intrinsic pathway (contact activation: FXII → FXI → FIX → FVIII) operate simultaneously to drive the common pathway (FX → prothrombin → thrombin → fibrin).
In hemophilia, FVIII (in hemophilia A) or FIX (in hemophilia B), key components of the intrinsic pathway, are absent or have greatly reduced function. FVIII, as a cofactor of the tenase complex (FIXa-FVIIIa-Ca²⁺-phospholipid), amplifies FX activation by FIXa several thousand-fold. Without FVIII, FIXa alone cannot sufficiently activate FX, and as a result thrombin generation is greatly reduced and a fibrin clot is not properly formed.
In the NOS state, whether it is FVIII deficiency or FIX deficiency has not yet been confirmed, but both cases commonly result in dysfunction of the intrinsic tenase complex. This is confirmed in the laboratory as APTT prolongation, while the PT (reflecting the extrinsic and common pathways) remains normal. Severity is proportional to the residual activity of the deficient factor. Residual activity below 1% is classified as severe, 1–5% as moderate, and 5–40% as mild.
Because platelet aggregation and primary hemostasis occur normally, bleeding from small wounds such as skin abrasions stops well, whereas after deep tissue injury or surgical procedures that require secondary hemostasis (fibrin formation), bleeding persists or recurs. Sites such as the joint cavity, where the synovium richly expresses FIXa inhibitors (TFPI, etc.), are particularly vulnerable sites where hemarthrosis occurs repeatedly.
The symptoms of hemophilia NOS vary more with severity than with type (A or B). The symptom patterns according to the three severity categories are as follows.
Severe (FVIII or FIX activity below 1%): spontaneous bleeding is characteristic. The most common and characteristic symptom is hemarthrosis, in which blood collects in large joints such as the knees, ankles and elbows, causing swelling, warmth and severe pain. Repeated hemarthrosis leads to hemophilic arthropathy, progressing to synovial thickening, cartilage damage, joint deformity and loss of function. Intramuscular bleeding (hematoma) is also common; in particular, iliopsoas hematoma can cause lower limb paralysis through femoral nerve compression. Intracranial hemorrhage is rare but a life-threatening complication. Most severe patients are diagnosed before age 1.
Moderate (FVIII or FIX activity 1–5%): spontaneous bleeding is rare, but excessive bleeding occurs even after minor trauma. Patients have difficulty with hemostasis after surgery or procedures, and joint bleeding also occurs but less frequently than in severe cases. Some patients are first diagnosed in adolescence or adulthood.
Mild (FVIII or FIX activity 5–40%): a bleeding tendency is rarely apparent in everyday activities. Abnormal bleeding becomes evident only with a clear provoking event such as surgery, tooth extraction or childbirth. First diagnosis in adulthood is most frequent in this group, and the diagnostic process often begins when APTT prolongation is found incidentally on preoperative testing. The NOS code is used particularly often for these mild patients at the stage before they undergo type-confirmation testing.
Other symptoms may include oral mucosal bleeding, epistaxis (nosebleed), hematuria and gastrointestinal bleeding, but these are less specific than hemarthrosis or muscle hematomas.
The signs of hemophilia NOS are divided into clinical examination findings and laboratory findings.
Clinical examination findings: with active hemarthrosis, swelling, warmth, erythema and tenderness of the affected joint (mainly the knee, ankle or elbow) are observed, and the joint's range of motion is markedly reduced. With advanced hemophilic arthropathy, joint deformity, muscle atrophy and flexion contracture may appear. Muscle hematomas show swelling and tenderness of the affected muscle area and soft-tissue induration; iliopsoas hematoma can be suspected from maintenance of a hip-flexed position and sensory abnormalities in the femoral nerve distribution.
Laboratory findings: the most characteristic laboratory sign of hemophilia is isolated prolongation of the APTT (activated partial thromboplastin time). The PT (prothrombin time), thrombin time (TT), fibrinogen level and platelet count all remain within the normal range. When a mixing study (mixing the patient's plasma with normal plasma 1:1 and then remeasuring the APTT) is performed with a prolonged APTT, correction occurs, which means that the deficient factor has been replenished and coagulation normalized; this is used to differentiate it from the presence of an inhibitor.
Measuring FVIII:C (factor VIII activity) and FIX:C (factor IX activity) separately shows that one of the two is reduced. In the NOS state, the type is confirmed by performing both tests simultaneously to determine which factor is deficient. As special tests, the thrombin generation assay or thromboelastography (TEG/ROTEM) can be used to assess overall coagulation capacity.
Because von Willebrand disease (vWD) is accompanied by reduced FVIII:C, when reduced FVIII:C is found, von Willebrand factor (vWF) antigen and vWF ristocetin cofactor activity should also be measured to differentiate it from vWD type 2N or type 3.
Screening for hemophilia NOS takes place in two broad contexts: testing prompted by clinical suspicion in patients with a bleeding tendency, and incidental discovery through preoperative testing or family history checks.
First-line screening coagulation tests consist of the APTT, PT, platelet count and fibrinogen measurement. In hemophilia, the characteristic pattern is a prolonged APTT only, with the rest normal. When the APTT exceeds the upper limit of the normal reference range (usually 35–40 seconds), an abnormality of the intrinsic coagulation pathway is suspected.
As second-line testing, a mixing study is performed to differentiate whether the APTT prolongation is due to factor deficiency (corrected) or to an inhibitor or lupus anticoagulant (not corrected). If correction is confirmed, FVIII:C and FIX:C are measured simultaneously. If one of them is reduced, the type can be confirmed as deficiency of that factor. If both factors are normal, other causes such as FXI, FXI or FXII deficiency are investigated.
When there is a family history, screening can be performed in carrier females. Hemophilia A carriers often have FVIII:C activity reduced to about 40–60%, and the APTT may be prolonged to a borderline level or be within the normal range. In this case, genetic testing is the most accurate way to confirm carrier status. Neonatal screening for hemophilia, when there is a known family history, measures factor activity in cord blood (umbilical cord blood) immediately after birth. However, caution is needed in interpretation because FIX levels can be physiologically low in the neonatal period.
Prenatal diagnosis is performed by identifying the specific variant in fetal DNA via chorionic villus sampling (11–14 weeks of gestation) or amniocentesis (15–18 weeks of gestation), and applies when a pathogenic variant is known in at least one parent.
The definitive diagnosis of hemophilia NOS is made through stepwise testing, and the NOS code corresponds to the temporary diagnostic stage before the type is confirmed.
Step 1: basic coagulation tests. Screening for an intrinsic pathway abnormality with the APTT, PT, platelet count and fibrinogen measurement. If isolated APTT prolongation is confirmed, proceed to the next step.
Step 2: mixing study. The patient's plasma is mixed 1:1 with normal plasma, and the APTT is remeasured immediately and after 2 hours of incubation at 37°C. Immediate correction suggests factor deficiency; if there is no immediate correction or the prolongation worsens after incubation, a time-dependent inhibitor (such as the FVIII inhibitor of acquired hemophilia A) or lupus anticoagulant is suspected.
Step 3: factor activity measurement. FVIII:C and FIX:C are measured by a one-stage clotting method (1-stage clot-based assay) or a chromogenic substrate method (chromogenic assay). If reduced FVIII:C is confirmed, hemophilia A is suspected, and vWD type 2N is differentiated by measuring von Willebrand factor (vWF:Ag, vWF:RCo). If reduced FIX:C is confirmed, hemophilia B is confirmed.
Step 4: inhibitor testing (Bethesda assay). After the diagnosis of hemophilia is confirmed, particularly when the treatment response is poor or there is a history of prior FVIII/FIX product administration, the inhibitor titer is measured by the Bethesda assay. A titer of 5 BU/mL or higher is classified as a high-titer inhibitor.
Step 5: genetic testing. For hemophilia A, intron 22 inversion testing is performed first; if negative, testing proceeds to intron 1 inversion and then sequencing of the entire F8 gene. For hemophilia B, sequencing of the entire F9 gene is performed. Genetic test results are used for carrier identification within the family, prenatal diagnosis and prediction of the risk of inhibitor development. Once the type is confirmed through all these steps, the NOS code is replaced by the confirmed code D66 (hemophilia A) or D67 (hemophilia B).
Treatment of hemophilia NOS is divided into the stage before type confirmation and the stage after.
Emergency treatment before type confirmation: when there is life-threatening bleeding (intracranial hemorrhage, airway bleeding, intra-abdominal bleeding, etc.) and it is difficult to wait for the type-confirmation results, fresh frozen plasma (FFP) can be given as a temporary measure. Because FFP contains both FVIII and FIX, it can be used regardless of type. However, it is difficult to raise blood levels of FVIII or FIX sufficiently with FFP alone, and there is a risk of volume overload. While type confirmation is delayed, recombinant activated FVII (rFVIIa, NovoSeven) may also be considered as bypassing agent therapy.
Treatment after type confirmation — hemophilia A (FVIII deficiency): in mild patients, desmopressin (DDAVP, Desmoapp) can be given to release endogenous FVIII. Moderate and severe patients use FVIII concentrates (plasma-derived or recombinant). Extended half-life (EHL) recombinant FVIII products have simplified prophylaxis to dosing 1–2 times per week. Emicizumab (Hemlibra) is a bispecific antibody that binds FIXa and FX simultaneously, a subcutaneous injection that substitutes for FVIII. It can be used regardless of the presence of inhibitors, with dosing options of once weekly, once every 2 weeks, or once every 4 weeks. Fitusiran is an siRNA-based subcutaneous injection that inhibits antithrombin to amplify thrombin generation, and as of 2025 it is available for both hemophilia A and B. Gene therapy (Valoctocogene Roxaparvovec) is the first AAV-based gene therapy approved in the EU for hemophilia A, in 2022.
Treatment after type confirmation — hemophilia B (FIX deficiency): extended half-life recombinant FIX products (e.g., eftrenonacog alfa-Fc, albutrepenonacog alfa) are given once weekly or every other week. Fitusiran is also applicable to hemophilia B. Gene therapy (etranacogene dezaparvovec) has also been approved in the EU for hemophilia B. When inhibitors develop, bypassing agent therapy (rFVIIa, APCC) is used and immune tolerance induction (ITI) is attempted.
The prognosis of hemophilia, including hemophilia NOS, has improved dramatically over the past several decades with advances in treatment. Before the 1960s, severe arthropathy, muscle atrophy and early death from intracranial hemorrhage were frequent, but the life expectancy of hemophilia patients currently receiving appropriate prophylaxis has reached a level nearly equal to that of the general population.
One of the most important factors affecting prognosis is whether an inhibitor develops. In about 25–30% of patients with severe hemophilia A, neutralizing antibodies (inhibitors) against FVIII products develop, which complicates treatment and makes bleeding control difficult, leading to progression of arthropathy and reduced quality of life. The risk of inhibitor development is determined by a variety of factors, including the gene variant type, history of FVIII exposure, and immune genes (HLA, etc.).
Joint health is another important indicator of prognosis. Patients who started prophylaxis in infancy can maintain near-normal joint status into adulthood, but patients diagnosed late or whose treatment was delayed may experience complications such as pain, functional limitation and joint replacement due to chronic hemophilic arthropathy. If the NOS state persists for a long time and type confirmation is delayed, appropriate factor administration is delayed, which can lead to an accumulation of bleeding complications.
HIV infection had a major impact on many hemophilia patients through the contamination of blood products in the 1980s, but modern virus-inactivated plasma-derived products and recombinant products carry no risk of infection transmission. Hepatitis C was also transmitted through contaminated blood products during this period, but it is now treatable with direct-acting antivirals (DAA). With the emergence of new treatment options such as emicizumab, fitusiran and gene therapy, the prognosis of hemophilia patients is expected to improve further.
Prevention in hemophilia NOS takes place on three levels: prevention of bleeding (primary prevention), prevention of diagnostic delay, and prevention of complications.
Primary prevention — factor prophylaxis: in patients with severe hemophilia, regular prophylactic factor infusion started at the first bleeding event or before age 2 is the standard of care. This prevents blood from collecting in the joints, suppressing the development of hemophilic arthropathy and reducing serious bleeding complications such as intracranial hemorrhage. The World Federation of Hemophilia (WFH) recommends primary prophylaxis for all patients with severe hemophilia. With the advent of emicizumab, prophylaxis can be maintained easily by subcutaneous injection, greatly improving the convenience of treatment.
Prevention of diagnostic delay: when APTT prolongation is found on preoperative or routine testing, it is important not to overlook it and to confirm the type immediately by measuring FVIII:C and FIX:C. When there is a family history, factor activity is measured in the neonatal period to secure an early diagnosis. It is recommended that the NOS state be used only as a temporary code and that type-confirmation testing be performed as quickly as possible.
Genetic counseling and prenatal diagnosis: women identified as hemophilia carriers should receive genetic counseling when planning pregnancy, and the genetic status of the fetus can be determined by prenatal diagnosis or preimplantation genetic testing (PGT). When a male infant is expected, cooperation with a specialist hemophilia team is needed in delivery planning, which covers the choice between cesarean section and vaginal delivery, avoidance of vacuum extraction and forceps delivery, and measurement of cord blood factor activity immediately after delivery.
Lifestyle and environmental prevention: avoid contact sports and high-risk activities, and refrain from taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) and antiplatelet agents. Avoid or minimize all intramuscular injections, preferring subcutaneous or intravenous administration. Maintain thorough oral hygiene to reduce the need for dental procedures such as tooth extraction. Factor activity, inhibitors, joint status, etc. are monitored periodically through regular follow-up at a specialist hemophilia center.